Navigation Links
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
Date:6/15/2009

SYDNEY, June 16 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) is pleased to announce that additional results of its recently completed international Phase III trial of Bronchitol in patients with cystic fibrosis have been presented at the 2009 European Cystic Fibrosis Conference in Brest, France.

The results were presented to the conference on Friday 12 June by Dr Diana Bilton of the Royal Brompton Hospital, London.

The trial was a multi-centre, randomised, double blind, placebo controlled, 26 week study, with an optional further 6 month open label uncontrolled period. It was conducted in 40 centres in the United Kingdom, Ireland, Australia and New Zealand.

The primary endpoint of the trial was to assess whether Bronchitol improves lung function as measured by a change in FEV1 when administered twice per day for six months.

The key secondary endpoint of the trial was to assess whether Bronchitol further improves lung function in patients already being treated with the most commonly used CF therapeutic, rhDNase. Additional endpoints included changes in the Forced Vital Capacity of the lung, pulmonary exacerbations and antibiotic use.

Safety evaluation included the incidence of adverse events and the microbiology of sputum samples.

    Clinical Results
    -- There was a clinically meaningful change from baseline (119mL) and
       placebo (93mL) at week 26 with Bronchitol for FEV1 (p<0.001).
       Importantly, treatment with Bronchitol showed an immediate and
       sustained improvement in lung function (FEV1) over the 26 weeks
       (p<0.001).
    -- For the subgroup of patients on concomitant rhDNase there was also a
       significant improvement in FEV1 from baseline (88mL) and from placebo
       (109mL) at we
'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... two universities and NPL collaborate to bring together their ... their complementary academic strengths., Working with BIS and NPL ... priorities of the UK. The establishment of a Graduate ... students, will provide a pipeline of skilled researchers. Working ... Laboratory will be grown through the creation of a ...
(Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a group ... is teaming up with the Heartland Blood Center and offering ... drive. The drive takes place Saturday, Jan. 18 at the ... 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health , ... change technology, today announces that EmblemHealth , the ... wellness company, is now providing the RedBrick Compass health ... program, to all of its members. EmblemHealth is among ...
Breaking Biology Technology:Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... Ariz., April 23 ImaRx Therapeutics,Inc. (Nasdaq: ... into an agreement,with Abbott Laboratories pursuant to which ... non-recourse promissory note with Abbott issued in,connection with ... title to,the urokinase assets, including the remaining inventory ...
... (NYSE: SGP ) today announced two agreements ... in Europe. These agreements are,in connection with conditions ... its October 2007 clearance of Schering-Plough,s acquisition of ... In two separate agreements, Pfizer and Virbac, ...
... today,announced that on April 22, 2008 its management ... Emerging Business Awards, known as the "Bennies.",BioNanomatrix won ... group of growing entrepreneurial firms in the Philadelphia ... the,award on behalf of the company., The ...
Cached Biology Technology:ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 3Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe 2BioNanomatrix Named 'Best Management Team' at the 2008 Ben Franklin Emerging Business Awards 2
(Date:7/10/2014)... This news release is available in German . ... scientists, including researchers from DESY, has caught a central step ... led by Prof. Petra Fromme from Arizona State University used ... Accelerator Laboratory SLAC to record still frames of a molecular ... and oxygen, a process that maintains the oxygen in earth,s ...
(Date:7/10/2014)... While careful management has helped stabilize or even ... parts of Europe, the situation in the Mediterranean ... a new report evaluating nine fish species reported ... on July 10, scientists call for stringent ... fisheries regulations, and advanced management plans in Mediterranean ...
(Date:7/10/2014)... of overfishing in the English Channel has resulted in ... and left fishermen ,scraping the barrel, for increasing amounts ... cod, haddock and many other species at the head ... many removed from the area completely., These are some ... biologists at Plymouth University, in association with international non-profit ...
Breaking Biology News(10 mins):Scientists watch photosynthesis in action 2Scientists watch photosynthesis in action 3Mediterranean fish stocks show steady decline 2Overfishing in the English Channel leaves fisherman scraping the bottom of the barrel 2Overfishing in the English Channel leaves fisherman scraping the bottom of the barrel 3
... paper being presented in two American Physiological Society ... team demonstrated "for the first time that mitochondria ... mitochondria may mechanically regulate nuclear function." , The ... years, reported that it recently "found a very ...
... There's no doubt that laughter feels good, but is ... do about it? , In a paper being presented ... 2006, Lee S. Berk of Loma Linda University, reports ... but just the anticipation of the "mirthful laughter" involved ...
... different plant species are not only more productive, they ... climate extremes, pests and disease over long periods of ... issue of Nature, are the culmination of 12 years ... Ecology at the University of Minnesota, to explore the ...
Cached Biology News:First direct mechanical communication of mitochondria, cardiomyocyte nucleus shown 2First direct mechanical communication of mitochondria, cardiomyocyte nucleus shown 3Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent 2Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent 3Biodiversity key to sustainable biofuel according to University of Minn. researcher's findings 2
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
... Virgin, optically clear polystyrene with frosted ... coordinates for cell counting. 100% integrity ... a new product number, created to ... showing no availability yet, please order ...
... CellBIND surface is produced by a ... more hydrophilic surface giving more consistent, ... and yields. CellBIND enhances cell attachment ... reduced serum or serum-free medium. • ...
Biology Products: